APA (7th ed.) Citation

SW, I., RD, F., P, H., AA, K., M, M., L, R., . . . Y, W. (2023). A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism. JBMR plus, 7(7), e10758. https://doi.org/10.1002/jbm4.10758

Chicago Style (17th ed.) Citation

SW, Ing, Finkelman RD, He P, Khan AA, Mannstadt M, Rejnmark L, Song I, Takács I, and Wu Y. "A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism." JBMR Plus 7, no. 7 (2023): e10758. https://doi.org/10.1002/jbm4.10758.

MLA (9th ed.) Citation

SW, Ing, et al. "A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism." JBMR Plus, vol. 7, no. 7, 2023, p. e10758, https://doi.org/10.1002/jbm4.10758.